Improving adherence to urate-lowering therapy in people living with gout
Int J Rheum Dis
.
2019 Apr;22(4):542-544.
doi: 10.1111/1756-185X.13566.
Authors
Matthew J Coleshill
1
2
,
Eindra Aung
1
2
,
Amy D Nguyen
1
3
,
Sophie L Stocker
1
2
,
Melissa T Baysari
4
,
Bishoy Kamel
1
2
,
Marcel Schulz
1
2
,
Andrew J McLachlan
5
,
Richard O Day
1
2
Affiliations
1
St Vincent's Clinical School, UNSW Medicine, Sydney, New South Wales, Australia.
2
Department of Clinical Pharmacology and Toxicology, St Vincent's Hospital, Sydney, New South Wales, Australia.
3
Centre for Health Systems & Safety Research, Australian Institute of Health Innovation, Macquarie University, Sydney, New South Wales, Australia.
4
Faculty of Health Sciences, University of Sydney, Sydney, New South Wales, Australia.
5
Sydney Pharmacy School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
PMID:
30985997
DOI:
10.1111/1756-185X.13566
No abstract available
Publication types
Editorial
Comment
MeSH terms
Gout Suppressants
Gout*
Humans
Uric Acid*
Substances
Gout Suppressants
Uric Acid